Capital Analysts LLC’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History
Bought
Maintained
Sold
Other funds holding BIB
SFS
HF
CIC
TFA
CIA
UMC
Capital Analysts LLC's BIB Position: Q4 2020 in Review
Capital Analysts LLC sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2020, closing a stake of 1,500 shares — an estimated $105K sold.
Capital Analysts LLC first reported a position in BIB in Q1 2014 and held it in 26 quarters. The position peaked at $156K in Q2 2015. 34 funds tracked by Wall St. Rank hold BIB as of Q4 2020.
- Capital Analysts LLC reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2020 after selling out during the quarter.
- Capital Analysts LLC sold 1,500 ProShares Ultra NASDAQ Biotechnology shares in Q4 2020, an estimated $105K.
- Capital Analysts LLC first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2014 and held it in 26 quarters.
- Capital Analysts LLC's ProShares Ultra NASDAQ Biotechnology position peaked at $156K in Q2 2015.
- 34 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2020.
Based on Capital Analysts LLC's 13F filing for Q4 2020, filed 16 Feb 2021.